Mexican Delphi Consensus to Use Favipiravir in Patients with COVID 19 (Expert Panel)

Abstract

Background and Objectives:The SARS COV2 pandemic in 2020 associated with severe pneumonia has been the most prevalent clinical entity in the morbidity and mortality of the disease. New antiviral treatments have been used under different emergency protocols with the aim of reducing the spread of the virus and reducing its lethality. Since 2013, favipiravir is an antiviral used to treat resistant influenza. Recently, multiple studies in Japan, Russia and China have demonstrated its effectiveness under the inhibitory mechanism of the viral RNA polymerase, effectively reducing the multiplication of the virus. The result of the expert panel using the Delphi method on the use of Favipiravir in patients with COVID 19 in Mexico is presented.Methods: Using the Delphi method and a panel of experts, a questionnaire was developed that included a block of questions regarding the benefit and non-benefit of the treatment of a patient with COVID 19 since diagnosis, identification of risk factors and comorbidities, as well as the ideal candidate. by consensus to receive the therapy, its follow-up, laboratory and office studies to be determined. There was consensus on determining the use of Favipiravir in routine clinical practice. Conclusion:The consensus determined the proper use of Favipiravir in patients with COVID 19 infection under the circumstances of the patient's risk, as well as the benefit of its dosage and monitoring in order to reduce the progression of the disease and reduce the demonstrated morbidity and mortality. in the 2020 pandemic.